MGMindy Goldman

Mindy Goldman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mindy Goldman has a total of 31 co-authors. Here are the top co-authors by number of shared publications:

  • Anne Long

    From the Canadian Blood Services, Ottawa, Ontario; and Héma‐Québec, Sainte‐Foy, Quebec, Canada

    3 shared publications
  • Francine Decary

    Héma‐Québec, 4045 Côte Vertu, Saint‐Laurent, PQ H4R 2W7 (Canada)

    2 shared publications
  • Qi-Long Yi

    Canadian Blood Services; Ottawa Ontario Canada

    2 shared publications
  • Shefali S. Ram

    From the Canadian Blood Services, Ottawa; and the Department of Pathology and Laboratory Medicine and the Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, Ontario, Canada

    2 shared publications
  • Sheila F. O'Brien

    Canadian Blood Services, Ottawa, Ontario, Canada

    2 shared publications
  • Alan J. Forster

    Ottawa Hospital Research Institute, Ottawa, Ontario, Canada

    1 shared publication

Latest Publications

  • Risk of exposure to blood products during pregnancy: guidance for Zika and other donor deferral policies

    by Malia S.Q. Murphy, Nadine Shehata, Jo Ann Colas, Michaël Chassé, Dean A. Fergusson, Sheila F. O'Brien, Mindy Goldman, Alan Tinmouth, Alan J. Forster, Kumanan Wilson

    Exposure to blood products during pregnancy carries a potential risk of transfusion transmission of infectious agents. Blood agencies have historically sought optimal deferral and testing strategies to protect blood supplies in part to ensure the protection of pregnant women and their unborn infants. The Zika virus outbreak of 2016 has heightened attention to these concerns. In the current context of the recent Zika outbreak, and also more broadly, data are needed to shed light on the likelihood of exposure to blood products throughout pregnancy to inform policy. Hospital administrative data from a large tertiary care center were examined for outpatient and nondelivery inpatient transfusion events in pregnant women between January 1, 2007, and December 31, 2013. Those pregnancies resulting in miscarriage were excluded from analysis. A total of 45,179 pregnancies resulting in delivery of a live or stillborn infant were documented at The Ottawa Hospital during the study period. Our findings indicate that 0.124%, or 1240 in 1,000,000, expectant mothers received transfusion at some point during their pregnancies with 0.04%, or 400 per 1,000,000, expectant mothers receiving a transfusion in the first trimester. Data from a large tertiary care center suggest that the risk of maternal and fetal exposure to blood products by transfusion during any stage of pregnancy is very low. Such a low likelihood of transfusion should be taken into consideration when developing donor deferral policies designed to protect women against transfusion-associated infection transmission during pregnancy and could inform evaluations of the risk of prenatal transfusion transmission of the Zika virus.


  • Donor deferral policies for men who have sex with men

    by Mindy Goldman, Sheila F. O’brien

    The review summarizes recent publications on the contentious issue of donor deferral criterion for men who have sex with men (MSM). Recent studies from the United States and China demonstrated that MSM is still a frequent risk factor for HIV-positive donors. Noncompliance is an important factor in the overall risk of HIV transmission but does not appear to be affected by the length of the deferral period. A major US study found a 2.6% noncompliance rate with the current indefinite deferral for MSM; similar or lower rates were found in other jurisdictions with shorter deferral periods. Several countries have had a defined deferral period of 1 year or 5 years in place long enough to determine that increases in HIV-positive cases predicted by modeling studies did not actually occur, suggesting that the assumptions made in these models are overly conservative. In summary, MSM eligibility policies are slowly changing around the world, with the US FDA now permitting a 1-year deferral. Transparency, involvement of stakeholders, and careful evaluation of risk and societal benefit should be part of future policy discussions on this issue.


  • Evaluation of selective screening of donors for antibody toTrypanosoma cruzi: seroprevalence of donors who answer “no” to risk questions

    by Sheila F. O'Brien, Vito Scalia, Mindy Goldman, Wenli Fan, Qi-Long Yi, Mary Huang, Momar Ndao, Margaret A. Fearon

    Background Selective testing of donors for Trypanosoma cruzi infection relies on identification of at-risk donors with screening questions. Using risk modeling and a seroprevalence study, we evaluated the risk of questions failing to identify T. cruzi antibody–positive donors. Study Design and Methods The rate of donors with unreported risk was estimated by a telephone survey of 2677 donors who answered “no” to risk questions. The number of T. cruzi antibody–positive donors missed by risk questions was estimated from the product of this rate and the selective testing T. cruzi antibody–positive rate. The 95% confidence interval (CI) was estimated by Monte Carlo simulation. To test the model, 60,132 donors were tested for T. cruzi antibody (26% of donors in selected regions, Phase I). In Winnipeg, Manitoba, the highest-risk region, 26,915 donors were tested (92.5% of donors, Phase II). Results In the telephone survey, 21 (0.8%) donors reported risk factors that would have identified them for selective testing. Seven were born in Mexico or Central or South America, five had travel risk, and nine had mother or maternal grandmother risk. The 95% CI for predicted number of T. cruzi antibody–positive donors answering “no” to risk questions was 0.71 to 4.38. In Phase I, one Winnipeg donor confirmed positive but had answered risk questions correctly. No other positive donations were identified. Conclusion The estimated risk of T. cruzi–positive donors who answer “no” to risk questions is low and is confirmed by the seroprevalence among these donors.


  • The donor health assessment questionnaire: potential for format change and computer‐assisted self‐interviews to improve donor attention

    by Mindy Goldman, Shefali S. Ram, Qi‐Long Yi, John Mazerall, Sheila F. O'BRien

    BACKGROUND: The Canadian donor health assessment questionnaire (DHAQ) has developed gradually over many years. The purpose of this study was to determine whether the format and method of administration of the DHAQ influences donor attentiveness.STUDY DESIGN AND METHODS: Between May 2004 and September 2005, a total of 1397 donors participated in the study by completing the DHAQ by one of three methods: the current Canadian Blood Services (CBS) format and method of administration, which is partly self‐administered and partly interviewer‐administered (Method 1); the DHAQ reformatted to the AABB Uniform Donor Health Questionnaire format and self‐administered (Method 2); and an audiovisual computer‐assisted self‐interview (CASI; Method 3). This was followed by a short, scripted interview assessing recall of 17 specific items queried on the DHAQ. Time to completion of the DHAQ and degree of familiarity with computer use were also assessed.RESULTS: The percentages of donors identifying all 17 items correctly were 9.4, 20.9, and 34.8 percent and the mean percentages recall of items were 53.9, 56.0, and 69.8 percent with DHAQ administration Methods 1, 2, and 3, respectively (p < 0.0001). This difference was largely attributable to the poor recall of items queried as part of a list in Method 1. Mean times to complete the DHAQ were 3.1, 3.8, and 8.1 minutes for Methods 1, 2, and 3, respectively. More than 95 percent of donors had used a personal computer in the past year.CONCLUSION: The current format of the Canadian DHAQ is not optimal for donor attention to specific questions asked as part of a list. Attention was improved by use of AABB uniform donor history questionnaire format and was best with use of a CASI format.


  • The Canadian donor health assessment questionnaire: can it be improved?

    by Mindy Goldman, Shefali S. Ram, Qi-Long Yi, Sheila F. O'Brien


  • Recent Canadian experience with targeted hepatitis C virus lookback

    by Mindy Goldman, Lindsay Patterson, Anne Long

    BACKGROUND:  Targeted hepatitis C virus (HCV) lookback studies have been performed in Canada since 1995. The yield of HCV lookback has not been reassessed since the introduction of improved HCV screening tests.STUDY DESIGN AND METHODS:  Data were combined from the two Canadian blood suppliers to determine the yield of targeted HCV lookback performed on donors found to be HCV‐positive by antibody screening and/or nucleic acid testing (NAT) from the introduction of NAT in 1999 until January 1, 2005.RESULTS:  Lookback was performed on 498 donations from 176 HCV‐seropositive and two NAT‐only‐positive donors; 494 components had been transfused, and 160 components were traced to living recipients who underwent HCV testing. Seventy‐two percent of recipients of components derived from donations given before the introduction of second‐generation enzyme immunoassay (EIA) testing were HCV‐seropositive. Four recipients of components derived from donations tested by second‐ or third‐generation EIA, with or without NAT, were HCV‐seropositive. Two of these recipients tested HCV‐seropositive before transfusion, and a third was probably infected by transfusions before the introduction of HCV testing. The fourth recipient likely received a noninfectious transfusion, since five other recipients of components from subsequent donations made by this donor were seronegative.CONCLUSION:  When previous donations had been tested by second‐ or third‐generation EIA, the yield of HCV lookback was likely zero. Because HCV infection is relatively common in the general population and patients in Canada do not undergo pretransfusion testing, coincident infections in recipients may be erroneously attributed to transfusion. The regulatory requirement for HCV lookback should be reassessed.


  • Another stab at donor hemoglobin screening

    by Mindy R. Goldman


  • Proceedings of a Consensus Conference: Towards an Understanding of TRALI

    by Mindy Goldman, Kathryn E. Webert, Donald M. Arnold, John Freedman, Judith Hannon, Morris A. Blajchman